Bronchodilators Market Report 2026

The bronchodilators market size has grown strongly in recent years. It will grow from $35.31 billion in 2025 to $37.56 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing prevalence of asthma and copd, rising smoking rates, limited access to advanced inhalation devices, government initiatives for respiratory health, high incidence of air pollution-related respiratory disorders.

The bronchodilators market size is expected to see strong growth in the next few years. It will grow to $47.96 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to technological advancements in inhalation devices, growing adoption of personalized medicine, increasing telemedicine integration, rising demand for combination therapies, expansion in emerging markets healthcare infrastructure. Major trends in the forecast period include personalized bronchodilator therapy, remote patient monitoring & telemedicine, inhalation device innovation, combination drug therapies, pediatric & geriatric targeted treatments.

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to drive the growth of the bronchodilator market going forward. Chronic obstructive pulmonary disease is a progressive lung condition marked by chronic inflammation of the airways and airflow obstruction or limitation. Bronchodilators are used in COPD to relax the muscles surrounding the airways, helping to open them and improve breathing. For instance, in March 2023, according to a report by the Scottish Public Health Observatory, led by Public Health Scotland, a UK-based population health center, COPD rates began to rise as the impact of COVID-19 subsided. The rate in males increased from 83.2 to 97.6 cases per 100,000, while in females, it rose from 72.6 to 97.3. Therefore, the increasing prevalence of chronic obstructive pulmonary disease (COPD) is driving the growth of the bronchodilator market.

Major companies in the bronchodilator market are developing innovative products such as fixed-dose triple-drug combinations to better serve patients. A fixed-dose triple-drug combination is a medication that contains three active ingredients in a single formulation, each with a predetermined dose. For instance, in January 2023, Lupin, an India-based pharmaceutical company, launched DIFIZMA, a fixed-dose triple-drug bronchodilator combining indacaterol, glycopyrronium, and mometasone for asthma management. DIFIZMA is administered as a dry powder inhalation and is the only fixed-dose combination approved by the Drug Controller General of India (DCGI) for treating inadequately controlled asthma, improving lung function, enhancing symptom control, and reducing exacerbations.

In February 2023, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for $1.8 billion. The acquisition aimed to advance the development of novel treatments for uncontrolled hypertension and chronic kidney disease. This acquisition is expected to strengthen AstraZeneca’s respiratory portfolio, which includes several bronchodilator products. CinCor Pharma is a US-based clinical-stage biopharmaceutical company focused on developing bronchodilator-related therapies.

Major companies operating in the bronchodilators market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Novartis AG, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline plc, Merck & Co. Inc., AstraZeneca plc, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceutical plc, Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Viatris Inc., Mitsubishi Tanabe Pharma, Kissei Pharmaceutical Co.Ltd., Theron Pharmaceuticals.

North America was the largest region in the bronchodilators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchodilators market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bronchodilators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the bronchodilators market by increasing import costs for active pharmaceutical ingredients and advanced inhalation devices, leading to higher production expenses and potential delays. The segments most affected include Beta-Adrenergic and Anticholinergic bronchodilators, particularly in regions like North America and Europe that rely on imported components. However, tariffs are driving manufacturers to explore local sourcing and domestic production, which may foster innovation and reduce long-term supply chain risks. Overall, the market faces short-term cost pressures but potential efficiency gains in the long term.

The bronchodilators market research report is one of a series of new reports that provides bronchodilators market statistics, including bronchodilators industry global market size, regional shares, competitors with a bronchodilators market share, detailed bronchodilators market segments, market trends and opportunities, and any further data you may need to thrive in the bronchodilators industry. This bronchodilators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bronchodilators are medications that help make breathing easier by relaxing the muscles in the lungs and widening the airways (bronchi). They are commonly used to treat chronic conditions in which the airways become narrow and inflamed, such as asthma and chronic obstructive pulmonary disease (COPD).

The main types of bronchodilators include beta-adrenergic bronchodilators, anticholinergic bronchodilators, xanthine derivatives, and others. Beta-adrenergic bronchodilators are a class of drugs that bind to beta-adrenergic receptors in the smooth muscles of the airways, causing relaxation and dilation, which improves airflow and relieves symptoms such as wheezing, coughing, and shortness of breath. These medications are administered orally, via nasal inhalation, or by injection, and are used to treat asthma, COPD, allergic reactions, breathing difficulties, and other conditions. They are provided to hospitals, specialty clinics, and other end users.

The bronchodilators market consists of sales of albuterol (proair, ventolin, proventil), formoterol (foradil, perforomist), salmeterol (serevent), tiotropium (spiriva) and ipratropium (atrovent). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.